Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?: CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many studies in which CETP was tested in the plasma showed an inverse correlation between CETP and cardiovascular risk.
“On the other hand, many studies in which CETP was tested in the plasma showed an inverse correlation between CETP and cardiovascular risk [37, 103].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 52 · Cited by 31
- Authors
- Hovingh, G. K., Ray, K. K., & Boekholdt, S. M.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Venue
- Circulation
- Published
- 2015-08-04
- Volume
- 132
- Issue
- 5
- Pages
- 433-440
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1856265350
- Cited by
- 31
- References
- 52
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 1 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 9 · 2016: 8 · 2015: 4
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Regeneron Pharmaceuticals
- Kowa Company
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- cholesteryl ester transfer protein, CETP inhibition, cardiovascular risk reduction, hypercholesterolemia, lipoprotein metabolism, atherosclerosis
- MeSH terms
- Amides, Animals, Anticholesteremic Agents, Benzodiazepines, Cardiovascular Diseases, Disease Models, Animal, Esters, Humans, Lipid Metabolism, Inborn Errors, Quinolines, Rabbits, Risk Factors, Sulfhydryl Compounds, Treatment Outcome, Oxazolidinones, Mice, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
